Hrt Financial LP Gritstone Bio, Inc. Transaction History

Hrt Financial LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$0.62 - $2.35 $18,978 - $71,933	30,610 New	30,610 $18,000
Q1 2023 May 12, 2023	BUY	$2.13 - $3.74 $607,853 - $1.07 Million	285,377 New	285,377 $793,000
Q2 2022 Aug 12, 2022	SELL	$1.77 - $4.34 $397,379 - $974,364	-224,508 Reduced 82.92%	46,251 $111,000
Q1 2022 May 16, 2022	BUY	$4.03 - $12.19 $1.09 Million - $3.3 Million	270,759 New	270,759 $1.12 Million
Q1 2021 May 17, 2021	SELL	$4.07 - $27.11 $100,467 - $669,210	-24,685 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.57 - $4.22 $63,440 - $104,170	24,685 New	24,685 $97,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.